Literature DB >> 32038917

Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer.

Satomi Tanaka1, Junji Uchino1.   

Abstract

Entities:  

Year:  2019        PMID： 32038917      PMCID： PMC6987352          DOI： 10.21037/tlcr.2019.06.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  17 in total

1.  Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.

Authors:  Jean-Yves Douillard; Hélène Tribodet; Delphine Aubert; Frances A Shepherd; Rafael Rosell; Keyue Ding; Anne-Sophie Veillard; Lesley Seymour; Thierry Le Chevalier; Stephen Spiro; Richard Stephens; Jean Pierre Pignon
Journal:  J Thorac Oncol       Date:  2010-02       Impact factor: 15.609

2.  Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.

Authors:  Masahiro Tsuboi; Harubumi Kato; Kanji Nagai; Ryosuke Tsuchiya; Hiromi Wada; Hirohito Tada; Yukito Ichinose; Masahiro Fukuoka; Haiyi Jiang
Journal:  Anticancer Drugs       Date:  2005-11       Impact factor: 2.248

3.  Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

Authors:  R Arriagada; A Auperin; S Burdett; J P Higgins; D H Johnson; T Le Chevalier; C Le Pechoux; M K B Parmar; J P Pignon; R L Souhami; R J Stephens; L A Stewart; J F Tierney; H Tribodet; J van Meerbeeck
Journal:  Lancet       Date:  2010-03-24       Impact factor: 79.321

4.  Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.

Authors:  Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Shimoyama; Yasuhide Yamada; Tomohide Tamura
Journal:  Cancer Chemother Pharmacol       Date:  2007-05-05       Impact factor: 3.333

5.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Authors:  Karen Kelly; Nasser K Altorki; Wilfried E E Eberhardt; Mary E R O'Brien; David R Spigel; Lucio Crinò; Chun-Ming Tsai; Joo-Hang Kim; Eun Kyung Cho; Philip C Hoffman; Sergey V Orlov; Piotr Serwatowski; Jiuzhou Wang; Margaret A Foley; Julie D Horan; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

6.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

7.  Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Authors:  Glenwood D Goss; Chris O'Callaghan; Ian Lorimer; Ming-Sound Tsao; Gregory A Masters; James Jett; Martin J Edelman; Rogerio Lilenbaum; Hak Choy; Fadlo Khuri; Katherine Pisters; David Gandara; Kemp Kernstine; Charles Butts; Jonathan Noble; Thomas A Hensing; Kendrith Rowland; Joan Schiller; Keyue Ding; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

8.  Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.

Authors:  Hounai Xie; Hui Wang; Lin Xu; Meng Li; Yue Peng; Xianyun Cai; Zhen Feng; Wangang Ren; Zhongmin Peng
Journal:  Clin Lung Cancer       Date:  2018-05-26       Impact factor: 4.785

9.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Qing Zhou; Yi-Long Wu
Journal:  Lancet Oncol       Date:  2017-11-21       Impact factor: 41.316

Review 10.  Emerging ethnic differences in lung cancer therapy.

Authors:  I Sekine; N Yamamoto; K Nishio; N Saijo
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640
View more
  2 in total

1.  Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study.

Authors:  Chun-Wei Xu; Wen-Xian Wang; Dong Wang; Qi-Ming Wang; Xing-Xiang Pu; You-Cai Zhu; Jian-Hui Huang; Zong-Yang Yu; Zhao-Lei Cui; Xiao-Hui Chen; Jin-Luan Li; Yong Fang; Hong Wang; Wu Zhuang; Shi-Jie Lan; Xin Cai; Yin-Bin Zhang; Wen-Bin Gao; Li-Ping Wang; Ke-Lin She; Chuang-Zhou Rao; Yue-Fen Zhou; Mei-Yu Fang; Li-Yun Miao; Lei Lei; Tang-Feng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2020-10

2.  Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis.

Authors:  Wenqian Li; Hanfei Guo; Lingyu Li; Jiuwei Cui
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.